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Lectin-like oxidized low-density lipoprotein (LDL) receptor 1 
(LOX1) is a receptor that recognizes oxidized LDL (oxLDL). 
LOX1 is expressed in various cells, such as endothelial cells and 
macrophages.1 OxLDL binding to LOX1 results in induction of 
endothelial dysfunction, monocyte infiltration, and LOX1 acti-
vation via intracellular signaling and inflammatory substances. 
Specifically, oxLDL increases reactive oxygen species synthe-
sis, LOX1 expression, and foam cell formation in macrophages 
through LOX1 while inhibiting macrophage migration, thereby 
leading to accelerated atherosclerosis.2 Proinflammatory cyto-
kines may enhance the proteolytic function of metalloprotein-
ases such as ADAM10 and 17, which, in turn, may augment the 
cleavage of the extracellular domain of LOX1 and increase the 
serum soluble LOX1 (sLOX1) levels.3 Furthermore, oxLDL was 
reported to enhance sLOX1 release in human umbilical vein en-
dothelial cells in vitro.4 Therefore, sLOX1 may reflect not only 
an increase in the intracellular LOX1 expression by oxLDL, but 
also a proinflammatory status. Based on these findings, even 
though sLOX1 is mainly considered to be a predictive biomark-
er for estimating the occurrence of cardiovascular diseases in 
various disorders, sLOX1 was also found to be associated with 
the disease activity of rheumatoid arthritis (RA), which is a 
typical autoimmune disease affecting the joints.5 
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Lectin-like oxidized low-density lipoprotein (LDL) receptor 1 (LOX1) binds to oxidized LDL, which is associated with inflamma-
tion in various vascular disorders. Here, we aimed to investigate the potential of soluble LOX1 (sLOX1) as an indicator of antineu-
trophil cytoplasmic antibody-associated vasculitis (AAV) activity. Serum levels of sLOX1 in frozen samples from patients with 
AAV enrolled in a prospective observational cohort study at the Severance Hospital were measured using enzyme-linked immu-
nosorbent assay. Clinical and laboratory data were collected on the date when the blood sampling was performed. The associa-
tion between sLOX1 and clinical and laboratory data was assessed using Pearson’s correlation analysis. The median age of the re-
cruited 79 patients was 62.0 years, and 27 (34.2%) patients were men. The median Birmingham vasculitis activity score (BVAS), 
five-factor score, vasculitis damage index, and sLOX1 level were 6, 1, 3, and 911.9 pg/mL, respectively. Correlation analysis based 
on BVAS revealed that sLOX1 and total cholesterol were significantly inversely correlated with BVAS (r=-0.224, p=0.047 and r= 
-0.424, p<0.001, respectively). No significant correlations were observed between continuous variables and sLOX1 except for 
BVAS, although total cholesterol tended to correlate with sLOX1 (r=0.190, p=0.093). Additionally, sLOX1 was not influenced by sex, 
hypertension, diabetes mellitus, or the presence of pulmonary, cardiovascular, and renal involvement of AAV. In summary, sLOX1 
was inversely correlated with BVAS in AAV patients, which is different from other vascular diseases or inflammatory diseases. 
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vasculitis (AAV) is a small vessel vasculitides characterized by 
inflammation in intraparenchymal capillaries, arterioles, and 
venules. Based on clinical and pathological findings, AAV is cat-
egorized into three variants: microscopic polyangiitis (MPA), 
granulomatosis with polyangiitis (GPA), and eosinophilic gran-
ulomatosis with polyangiitis (EGPA).6,7 AAV pathogenesis is simi-
lar to the pathogenesis of atherosclerosis—mediated through 
oxLDL and LOX1—which involves endothelial dysfunction 
and macrophage activation via primed and activated neutro-
phils and circulating ANCA.8 Thus, theoretically, sLOX1 is ex-
pected to reflect the activity of AAV; however, this has not been 
investigated. Therefore, in this study, we evaluated the poten-
tial of sLOX1 as a biomarker to reflect the activity of AAV. 
Seventy-nine patients with AAV, who had been enrolled in 
the Severance Hospital ANCA associated VasculitidEs (SHAVE) 
cohort study from November 2016 to April 2019, were includ-
ed in this study. The SHAVE cohort is a prospective observa-
tional cohort of Korean patients with AAV. Blood samples of the 
patients are collected at a regular basis of every 3 to 6 months 
simultaneously using clinical and laboratory data, and patients’ 
sera are stored at -80°C upon isolation. Written informed con-
sents were obtained from patients when the blood sampling 
was performed. All patients enrolled in the cohort were diag-
nosed as AAV at Severance Hospital, and met the 2007 Europe-
an Medicines Agency algorithms for defining AAV and poly-
arteritis nodosa6 as well as the 2012 Chapel Hill Consensus 
Conferences Nomenclature of Vasculitis.7 Here, we used the 
patients’ clinical and laboratory data, including demographic 
data, AAV variants, ANCA positivity, clinical manifestations, 
vasculitic indices, comorbidities, and laboratory results, on the 
date when blood sampling was performed. Meanwhile, pa-
tients with serious medical conditions other than AAV, such as 
severe infections and malignancies, were excluded from this 
study. Vasculitic indices for AAV included Birmingham vascu-
litis activity score (BVAS),9 five-factor score (FFS) as proposed 
in 2009,10 vasculitis damage index (VDI),11 and the Korean ver-
sion of the short form 36-item Health Survey (SF-36) as a func-
tional index in AAV patients. SF-36 was scored and represent-
ed as both mental component score and physical component 
score.12 We evenly applied BVAS to MPA, GPA, and EGPA pa-
tients to normalize the scoring system, as BVAS for GPA has a 
different weight-system compared with BVAS. Medications 
that were prescribed to the patients for the treatment of dys-
lipidemia and AAV were also investigated by searching the 
electronic medical records of patients.
Serum sLOX1 levels were measured in stored samples with 
enzyme-linked immunosorbent assay kits (ab212161; Abcam, 
Cambridge, UK) in accordance with the manufacturer’s in-
structions. In addition, sera of 37 healthy controls were used 
to compare the level of sLOX1 in AAV and controls. This study 
was performed in accordance with the principles set by the 
Declaration of Helsinki and its later amendments, and was 
approved by the Institutional Review Board of Severance Hos-
Table 1. Clinical Characteristics of Patients 
Variables Values 
Demographic data
Age (yr) 62.0 (21.0)
Male sex 27 (34.2)






MPO-ANCA (or P-ANCA) positivity 45 (57.0)




Mucous membranes/eyes 5 (6.3)














Diabetes mellitus 14 (17.7)
Laboratory results 
White blood cell count (/mm3) 7700.0 (4620.0)
Haemoglobin (g/dL) 11.8 (3.8)
Platelet (×1000/mm3) 253.0 (134.0)
Fasting glucose (mg/dL) 101.0 (35.0)
Blood urea nitrogen (mg/dL) 18.9 (16.5)
Creatinine (mg/dL) 0.9 (1.6)
Total protein (g/dL) 6.4 (0.9)
Serum albumin (g/dL) 3.7 (0.9)
Aspartate aminotransferase (IU/L) 18.0 (9.0)
Alanine aminotransferase (IU/L) 18.0 (13.0)
ESR (mm/hr) 37.0 (42.0)
CRP (mg/L) 2.3 (14.6)
Total cholesterol (mg/dL) 188.6 (55.9)
sLOX1 (pg/mL) 911.9 (1372.1)
AAV, antineutrophil cytoplasmic antibody-associated vasculitis; MPA, micro-
scopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic 
granulomatosis with polyangiitis; ANCA, antineutrophil cytoplasmic antibody; 
MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, 
birmingham vasculitis activity score; FFS, five-factor score; VDI, vasculitis dam-
age index; SF36-PCS, short form 36-item health survey physical component 
score; SF36-MCS, short form 36-item health survey mental component score; 
ESR, erythrocyte sedimentation rate; CRP, c-reactive protein; sLOX1, soluble 
lectin-like oxidized low-density lipoprotein receptor 1. 
Values are expressed as a median (interquartile range) or number (%). 
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pital (4-2016-0901). All statistical analyses were conducted us-
ing SPSS software (version 23 for Windows; IBM Corp., Ar-
monk, NY, USA). Continuous variables were expressed as a 
median (interquartile range), and categorical variables were 
expressed as number (percentage). The correlation coefficient 
of continuous variables was obtained using the Pearson’s cor-
relation coefficient analysis. Significant differences in contin-
uous variables between the two groups were compared using 
the Mann–Whitney U and Kruskal-Wallis test. p-values< 0.05 
were considered statistically significant.
The median age of patients was 62.0 years, and 27 (34.2%) 
patients were men. The median BVAS, FFS, and VDI were 6, 1, 
and 3, respectively. Clinical and laboratory data are presented 
in Table 1. The median serum sLOX1 was 911.9 pg/mL, and 
patients with AAV had significantly lower sLOX1 level in the 
sera compared to healthy controls (p<0.001) (Supplementary 
Fig. 1, only online). Correlation analysis based on BVAS re-
vealed that sLOX1 and total cholesterol were significantly in-
versely correlated with BVAS (r=-0.224, p=0.047 and r=-0.424, 
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Fig. 1. Correlation between BVAS and continuous variables. The association between BVAS and (A) sLOX1, (B) FFS, (C) VDI, (D) ESR, (E) CRP, and (F) cho-
lesterol level was assessed using Pearson’s correlation analysis. BVAS, birmingham vasculitis activity score; sLOX1, soluble lectin-like oxidized low-den-
sity lipoprotein receptor 1; FFS, five-factor score; VDI, vasculitis damage index; ESR, erythrocyte sedimentation rate; CRP, c-reactive protein.
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and C-reactive protein were significantly positively correlat-
ed with BVAS (Fig. 1). However, correlation analysis based on 
sLOX1 did not reveal any significant correlations between these 
variables and sLOX1, except for BVAS, although total choles-
terol tended to correlate with sLOX1 (r=0.190, p=0.093) (Fig. 2). 
Furthermore, no difference was found in sLOX1 level regard-
ing the use of medications and disease variants (Supplemen-
tary Table 1 and Supplementary Fig. 2, only online). In addi-
tion, we found that the serum sLOX1 levels in these patients 
were not influenced by sex, hypertension, diabetes mellitus, 
or by the presence of pulmonary, cardiovascular, and renal 
involvement of AAV (Supplementary Fig. 3, only online). 
It has been demonstrated that inflammatory cytokines 
could increase sLOX1 by enhancing the enzymatic function of 
ADAM10 and 17, which releases sLOX1 as a result of proteo-
lytic cleavage.3 During the pathogenesis of AAV, the release of 
inflammatory cytokines from macrophages could promote 
ANCA production as well as neutrophil priming and activa-
tion, thereby triggering and exacerbating AAV.8 Therefore, in 
theory, BVAS—reflecting the activity of AAV—should be posi-
Fig. 2. Correlation between sLOX1 and continuous variables. The association between sLOX1 and (A) BVAS, (B) FFS, (C) VDI, (D) ESR, (E) CRP, and (F) 
cholesterol level was assessed using Pearson’s correlation analysis. sLOX1, soluble lectin-like oxidized low-density lipoprotein receptor 1; BVAS, bir-
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tively correlated with sLOX1; however, to our surprise, BVAS was 
significantly inversely correlated with sLOX1. 
A previous study has shown that serum level of sLOX1 and 
oxLDL is significantly elevated in patients with active Behçet's 
disease and systemic lupus erythematosus compared to healthy 
controls.13 In the present study, we did not measure the serum 
oxLDL, but measured the total serum cholesterol instead, 
which might be proportional to serum oxLDL. We found that a 
negative correlation between disease activity and sLOX1 was 
present; and when we compared sLOX1 with healthy controls, 
it was shown that the level of sLOX1 was significantly lower in 
AAV patients compared to healthy controls. Although the pre-
cise cause of this observation remains unknown, the decrease 
in total cholesterol could be attributed to this result. Total cho-
lesterol level could decrease in chronic inflammatory condi-
tions; in this context, it has been reported that patients with RA 
have lower total cholesterol level compared to the general pop-
ulation.14 Interestingly, a recent publication by Wallace, et al.15 
also reported that total cholesterol levels were suppressed pri-
or to treatment and elevated after 6 months of treatment in 
AAV patients, suggesting that lower total cholesterol levels are 
indicative of higher inflammation and disease activity. In fact, 
we also found that when the activity of AAV (BVAS) increases, a 
proportional decrease of total cholesterol level is observed (r= 
-0.424). Owing to the fact that the production of sLOX1 is main-
ly dependent on the increased concentration of oxLDL, which 
was shown in an in vitro experiment,4 it is possible that sLOX1 
is decreased in AAV as a consequence of decreased cholesterol 
levels. However, a report by Petermann Smits, et al.16 has shown 
that neither total cholesterol nor LDL levels were significantly 
different between AAV patients and controls. Given that the 
association between BVAS and total cholesterol level in AAV 
still remains controversial, further studies are required to elu-
cidate whether cholesterol profiles in the blood are correlated 
with the disease activity of AAV.
To the best of our knowledge, the strength of this study is 
that it is the first to investigate the potential of sLOX1 as a bio-
marker to assess the activity of AAV. However, our study had 
several limitations. First, although this was a prospective co-
hort study, we were not able to provide longitudinal informa-
tion on sLOX1 in AAV patients. Second, the number of patients 
included in this study was not large enough to represent all 
AAV patients. Third, our data cannot provide any mechanistic 
investigation into how sLOX1 could be directly linked to dis-
ease activity in AAV. Fourth, we were not able to evaluate LOX1 
expression in the affected tissues, which may provide more re-
liable information regarding the role of LOX1 in AAV. Finally, 
we could not enroll patients from other regions as a validation 
cohort to verify the findings of our study. 
In conclusion, our study demonstrates that sLOX1 is in-
versely correlated with BVAS in AAV patients, which is contrary 
to other vascular diseases or inflammatory diseases. Addition-
al studies are warranted to elucidate the clinical implication of 
sLOX1 in patients with AAV.
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